A COVID-19 vaccine being developed by the University of Oxford in collaboration with AstraZeneca Plc is producing a similar immune response in both older and younger adults, signaling hopes that the vaccine could be a frontrunner among the numerous vaccines in production and testing.
Adverse responses were also lower among the elderly, adding more promise to the vaccine's potential as a possible preventative measure against COVID-19.
The Oxford/AstraZeneca vaccine is expected to be one of the first from big pharma to secure regulatory approval, along with Pfizer and BioNTech’s candidate. Eric Sorensen reports.
For more info, please go to https://globalnews.ca/news/7421863/coronavirus-vaccine-astrazeneca-immune-response/
Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc
Like Global News on Facebook HERE: http://bit.ly/255GMJQ
Follow Global News on Twitter HERE: http://bit.ly/1Toz8mt
Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB
#GlobalNews #COVID19 #coronavirus
Adverse responses were also lower among the elderly, adding more promise to the vaccine's potential as a possible preventative measure against COVID-19.
The Oxford/AstraZeneca vaccine is expected to be one of the first from big pharma to secure regulatory approval, along with Pfizer and BioNTech’s candidate. Eric Sorensen reports.
For more info, please go to https://globalnews.ca/news/7421863/coronavirus-vaccine-astrazeneca-immune-response/
Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc
Like Global News on Facebook HERE: http://bit.ly/255GMJQ
Follow Global News on Twitter HERE: http://bit.ly/1Toz8mt
Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB
#GlobalNews #COVID19 #coronavirus
- Category
- U.S. & Canada
- Tags
- AstraZeneca, COVID-19 Vaccine, Coronavirus Vaccine
Sign in or sign up to post comments.
Be the first to comment